MASH / MASLD

The first half of 2025 recap for hepatology spotlights FDA approvals, clinical trial updates, and the 1-year anniversary of resmetirom.

The Q2 recap for hepatology spotlights regulatory approvals, clinical trial updates, and the launch of HCPLive’s flagship hepatology podcast.

The month in review spotlights hepatic regulatory news, new clinical trial data, and novel research about liver disease risk factors.

Jennifer Lai, MD, shares science-backed strategies for clinicians to counsel patients on nutrition and liver health.

This case study underscores how fragmented care and weight bias can contribute to late-stage MASH diagnosis.

A patient’s near-fatal journey from undiagnosed fatty liver disease to liver transplant highlights the urgent need for better screening and stigma-free communication.

Positive topline results show the trial met its primary endpoint for MASH resolution and fibrosis improvement, with significant weight loss effects without plateauing.

A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.

More frequently adding salt to food was associated with heightened risks of MASLD, cirrhosis, and hepatocellular carcinoma.

Patients with alcohol-associated liver disease and MetALD had greater risks of adverse liver outcomes and all-cause mortality than those with MASLD.

Findings highlight an increased risk of MASLD, heart failure, type 2 diabetes, and other cardiometabolic diseases following cycles of weight loss and regain.

In the second part of a 2-part episode, hosts Kimberly Brown and Nancy Reau break down 3 more notable abstracts from the 2025 EASL Congress.

The month in review spotlights hepatic podcast episodes from HCPLive, new clinical trial data, and coverage from DDW.

Alkhouri reviews data from the trial’s open-label compensated MASH cirrhosis arm demonstrating resmetirom’s impact on liver stiffness and CSPH.

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.

Hosts Kimberly Brown and Nancy Reau break down 4 of the top abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress.

Gyre Therapeutics plans to file an NDA in China based on the phase 3 CHB data and, pending IND clearance, is looking to initiate a phase 2 MASH fibrosis trial in the US.

Banerjee describes the value of multiorgan MRI for predicting cardiac and liver outcomes and cT1’s prognostic utility in liver disease.

Use of efruxifermin did not result in a significant reduction in fibrosis without worsening of MASH at week 36 compared with placebo in the phase 2b SYMMETRY trial.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

FibroX showed superior performance, interpretability, and potential cost savings relative to FIB-4, improving risk stratification and management in MASLD.

The month in review spotlights hepatic FDA and pipeline news as well as new research on alcohol and obesity's impact on liver health and PBC.

In this episode, hosts explore the promise of semaglutide 2.4 mg in improving liver outcomes for MASH in the Phase 3 ESSENCE trial.

New Phase 3 trial results reveal semaglutide's effectiveness in treating metabolic dysfunction-associated steatohepatitis, offering hope for millions.

Findings suggest the benefit of MASLD-focused anti-inflammatory interventions for promoting brain health and preventing accelerated brain aging.